Introduction Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have several features in common but also possess distinct differences. Synovial fibroblasts (SF) are known key effector cells in the pathophysiology of RA. We hypothesised that differential responses of SF from patients with PsA and RA to various stimuli including adipokines and cytokines may contribute to those differences. For example, IL-17 (also found in synovial tissue) is of particular therapeutic significance in PsA but not as effective in RA. Thus far, IL-17 in its isoform IL-17A has been the major therapeutic target in PsA but IL-17F also plays a role in the IL-23/IL-17 axis of inflammatory diseases. Objectives Therefore, we analysed the responses of SF from patients with PsA, RA or no rheumatic disease to IL-17A/F ±TNF-a and selected adipokines. Methods SF were isolated from patients with PsA, RA or nonrheumatic disease controls (N), each undergoing joint surgery. PsASF, RASF and NSF were stimulated with recombinant IL-17A/F, TNF-, visfatin, and resistin. A neutralising anti-IL-17A antibody was used to verify specificity of the IL-17A effects. Secretion of the proinflammatory cytokine IL-6 was used as the initial readout parameter and was quantified using a commerical immunoassay.
Results Stimulation with visfatin caused a strong increase in IL-6 secretion in all SF types (n=3 each), while resistin had no effect. Differences in responses were not statistically significant between the SF types studied. IL-17A at concentrations found in serum or synovial fluid did not induce IL-6 secretion in any of the SF. Dose-response curve analysis showed that considerably higher concentrations of IL-17A, which may occur locally in tissue, are required for the induction of IL-6 secretion. An anti-IL-17A antibody abolished the effect, thus showing that the effect is specific for IL-17A. The effects of IL-17A and IL-17F on IL-6 secretion by PsASF could be strongly amplified by a co-stimulation with TNF-a (IL-17A: 5-fold vs 113-fold; IL-17F: 1.7-fold vs 39-fold; TNF-a alone: 12-fold). The effects were stronger for IL-17A than for IL-17F with or without TNF co-stimulation. No effect of IL-17F alone was observed on NSF (n=1). Conclusions SF from RA and PsA were not differentially affected by the adipokines visfatin and resistin or IL-17A when used at serum or synovial fluid concentrations. The property of IL-17F not affecting NSF but PsASF (and RASF) may be beneficial in its use as therapeutic target.
Introduction Rheumatoid arthritis (RA) and osteoarthritis (OA) lead to joint destruction and disability. Although both diseases are characterised by inflammation of the joints as well as systemic inflammation, their pathogenesis is different. Despite the progress in the treatment both diseases are still incurable. Articular adipose tissue (AAT) and subcutaneous adipose tissue (ScAT) are supposed to contribute to joint and systemic inflammation, respectively. Our previous work showed that AAT from RA patients synthesises factors relevant to disease pathogenesis and/or progression and this secretion is usually higher from articular than subcutaneous adipose tissue.
1,2
Objectives The aims of present work were (i) to investigate whether AAT obtained from OA patients is also more active than ScAT and (ii) to compare secretory activity of adipose tissues from RA and OA patients. Methods AAT and ScAT explants obtained from OA [(n=44; female (F)/male (M)=36/8; age=62 (mean) (35-71) (minmax)] and RA (n=43; F/M=35/8; age=54 (31-70)] patients during knee joint replacement surgery were cultured (100 mg/ ml) for 24 hours in DMEM. Concentrations of proinflammatory (IL-6, TNF), anti-inflammatory (IL-1Ra, IL-10, TGFb) cytokines, chemokines (CCL2, CCL5) and metalloproteinase MMP-3 was measured in culture supernatants by ELISA. Results In both diseases AAT secreted spontaneously more IL1Ra, TGFb and MMP-3 than ScAT while the release of other factors was minute (TNF, IL-10, CCL5) or moderate (CCL2) and did not differ between tissues. The only exception was IL-6 produced in larger quantity by AAT than ScAT from OA patients. Both adipose tissues from OA patients released significantly more TNF, IL-1Ra and CCL2 than tissues from RA patients. Moreover, AAT from OA produced more MMP-3 than respective tissue of RA patients while rheumatoid ScAT secreted more TGFb. We did not find differences in basal secretion of IL-6, IL-10 and CCL5 between diseases. Conclusions Despite the fact, that similarly to RA the secretion of cytokines and chemokines in OA was usually higher in AAT than in ScAT, also the latter tissue released considerable quantity of tested factors and thus may contribute to systemic inflammation. Unexpectedly, our results give also evidence that basal secretory activity of adipose tissues from OA patients is usually higher than from RA patients. It is possibly caused by
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